Literature DB >> 9135549

A comparative study of the in vitro immunomodulatory activity of human intact immunoglobulin (7S IVIG), F(ab')2 fragments (5S IVIG) and Fc fragments. Evidence for post-transcriptional IL-2 modulation.

D Nachbaur1, M Herold, B Eibl, H Glassl, H Schwaighofer, C Huber, A Gächter, M Pichl, D Niederwieser.   

Abstract

During the past few decades intravenous immunoglobulin (IVIG) has been used successfully in the treatment of various immunoregulatory disorders. Treatment results have been attributed to immunomodulation mainly via Fc receptors or by anti-idiotypic antibodies to disease-causing autoantibodies. From the present study it is clearly evident that 7S IVIG (intact immunoglobulin) as well as 5S IVIG [F(ab')2 fragments] and Fc fragments have a potent immunomodulatory capacity. We demonstrate that mainly 7S IVIG inhibits alloantigen-induced T-cell proliferation and generation of cytotoxic T lymphocytes. Reduced interleukin-2 (IL-2) protein levels in culture supernatants of IVIG-supplemented mixed lymphocyte reactions (MLR) but unchanged IL-2 mRNA levels strongly argue in favour of a post-transcriptional interference of IVIG with cytokines and/or cytokine production. Interferon-gamma (IFN-gamma), soluble IL-2 receptor (sIL-2R) and monokines such as IL-1 beta, IL-6, IFN-alpha and tumour necrosis factor (TNF-alpha) were not affected by IVIG supplementation to MLR. Fc fragments were superior to F(ab')2-containing IVIG (5S and 7S IVIG) in inhibiting lectin stimulation of peripheral blood mononuclear cells (PBMC), whereas natural killer (NK) cytotoxicity was primarily inhibited by Fc-bearing IVIG (7S IVIG and Fc fragments), suggesting multiple mechanisms of IVIG immunomodulatory activity.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9135549      PMCID: PMC1456751          DOI: 10.1046/j.1365-2567.1997.d01-2148.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  33 in total

1.  Evidence for immunosuppression by high-dose gammaglobulin.

Authors:  K Kawada; P I Terasaki
Journal:  Exp Hematol       Date:  1987-02       Impact factor: 3.084

2.  The treatment of Kawasaki syndrome with intravenous gamma globulin.

Authors:  J W Newburger; M Takahashi; J C Burns; A S Beiser; K J Chung; C E Duffy; M P Glode; W H Mason; V Reddy; S P Sanders
Journal:  N Engl J Med       Date:  1986-08-07       Impact factor: 91.245

3.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

Authors:  P Chomczynski; N Sacchi
Journal:  Anal Biochem       Date:  1987-04       Impact factor: 3.365

4.  Quantification and characterization of high-affinity membrane receptors for tumor necrosis factor on human leukemic cell lines.

Authors:  P Scheurich; U Ucer; M Krönke; K Pfizenmaier
Journal:  Int J Cancer       Date:  1986-07-15       Impact factor: 7.396

5.  Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin.

Authors:  Y Sultan; M D Kazatchkine; P Maisonneuve; U E Nydegger
Journal:  Lancet       Date:  1984-10-06       Impact factor: 79.321

6.  Modulation of mononuclear phagocyte function by intravenous gamma-globulin.

Authors:  R P Kimberly; J E Salmon; J B Bussel; M K Crow; M W Hilgartner
Journal:  J Immunol       Date:  1984-02       Impact factor: 5.422

7.  A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity.

Authors:  A P Feinberg; B Vogelstein
Journal:  Anal Biochem       Date:  1983-07-01       Impact factor: 3.365

8.  Human large granular lymphocytes and their relationship to natural killer cell activity in various disease states.

Authors:  G Gastl; D Niederwieser; C Marth; H Huber; D Egg; G Schuler; R Margreiter; H Braunsteiner; C Huber
Journal:  Blood       Date:  1984-07       Impact factor: 22.113

9.  Use of donor-specific T-cell lines for monitoring of human allograft recipients. I. Demonstration of IgG binding to autologous TCL.

Authors:  C Huber; E Irschik; E Leiter; H Binz; D Niederwieser; M Spielberger; H Kathrein; D Schönitzer; R Margreiter
Journal:  Exp Cell Biol       Date:  1986

10.  A rapid colorimetric assay for the determination of IL-2-producing helper T cell frequencies.

Authors:  K Heeg; J Reimann; D Kabelitz; C Hardt; H Wagner
Journal:  J Immunol Methods       Date:  1985-03-18       Impact factor: 2.303

View more
  6 in total

Review 1.  Facing the enigma of immunomodulatory effects of intravenous immunoglobulin.

Authors:  Tal Sapir; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

2.  Cytokine modulation with immune gamma-globulin in peripheral blood of normal children and its implications in Kawasaki disease treatment.

Authors:  M Gupta; G J Noel; M Schaefer; D Friedman; J Bussel; R Johann-Liang
Journal:  J Clin Immunol       Date:  2001-05       Impact factor: 8.317

3.  Antibody-mediated protection in murine Cryptococcus neoformans infection is associated with pleotrophic effects on cytokine and leukocyte responses.

Authors:  Marta Feldmesser; Aron Mednick; Arturo Casadevall
Journal:  Infect Immun       Date:  2002-03       Impact factor: 3.441

4.  Modulation of alloimmune response in vitro by an IgM-enriched immunoglobulin preparation (Pentaglobin).

Authors:  D Nachbaur; M Herold; A Gächter; D Niederwieser
Journal:  Immunology       Date:  1998-06       Impact factor: 7.397

5.  Effect of immunoglobulin G (IgG) interchain disulfide bond cleavage on efficacy of intravenous immunoglobulin for immune thrombocytopenic purpura (ITP).

Authors:  Y Machino; H Ohta; E Suzuki; S Higurashi; T Tezuka; H Nagashima; J Kohroki; Y Masuho
Journal:  Clin Exp Immunol       Date:  2010-10-05       Impact factor: 4.330

6.  High Dose Intravenous IgG Therapy Modulates Multiple NK Cell and T Cell Functions in Patients With Immune Dysregulation.

Authors:  Sarah M McAlpine; Sarah E Roberts; John J Heath; Fabian Käsermann; Andrew C Issekutz; Thomas B Issekutz; Beata Derfalvi
Journal:  Front Immunol       Date:  2021-05-19       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.